Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide (1) and is the major indication for liver transplantation in the United States (2, 3). While therapy with PEGylated Interferon-alpha (PEG-IFN) plus ribavirin (RBV) provides sustained virologic response (SVR) in 40-50% of patients overall, the SVR rate is only about 20% in African Americans and Hispanics, who have a higher frequency of single nucleotide polymorphisms associated with poor response (4, 5). Addition of direct-acting antivirals (DAAs) targeting the HCV NS3/4A protease increases SVR rates to 68-75% in previously untreated patients, but such regimens still suffer from the limitations of PEG-IFN/RBV. Thus, drug developers are seeking combinations of DAAs that will reduce or eliminate the need for PEG-IFN and/or RBV while providing an adequate barrier to resistance. It was recently reported that a small number of genotype 1a and 1b patients achieved SVR following treatment with a combination of two DAAs targeting NS3/4A and NS5A. While these results provide proof of concept for SVR without use of PEG-IFN/RBV, biological data to inform the selection of such DAA combinations are limited. The preponderance of preclinical characterization of DAAs and combinations has been obtained using subgenomic HCV replicons in Huh-7 hepatoma-derived cell lines, a recombinant system that omits important features of the viral life cycle. Systems have been developed that recapitulate the complete HCV life cycle in hepatoma lines and primary human hepatocytes/hepatoblasts. This study proposes to interrogate the effects of DAAs in cell systems that support the complete HCV life cycle. These studies will deepen our understanding of key biological processes involved in viral replication and provide new insights into DAA mechanisms of action that will be translatable to clinical studies.

Public Health Relevance

Hepatitis C virus (HCV) is a major public health burden, with approximately 130 million people infected worldwide, and HCV-associated liver disease is the main indication for liver transplant in the United States. We propose to characterize direct-acting antiviral agents and identify combinations with the greatest ability to eliminate infection by usin state of the art analytical methods and cell culture systems that reproduce the complete HCV life cycle in primary human hepatocytes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI099284-02
Application #
8463990
Study Section
Special Emphasis Panel (ZAI1-LG-M (J2))
Program Officer
Koshy, Rajen
Project Start
2012-05-01
Project End
2017-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
2
Fiscal Year
2013
Total Cost
$691,240
Indirect Cost
$178,222
Name
Rockefeller University
Department
Microbiology/Immun/Virology
Type
Other Domestic Higher Education
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Salie, Zhe Li; Kirby, Karen A; Michailidis, Eleftherios et al. (2016) Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA). Proc Natl Acad Sci U S A 113:9274-9
Scheel, Troels K H; Luna, Joseph M; Liniger, Matthias et al. (2016) A Broad RNA Virus Survey Reveals Both miRNA Dependence and Functional Sequestration. Cell Host Microbe 19:409-23
Ramanan, Vyas; Trehan, Kartik; Ong, Mei-Lyn et al. (2016) Viral genome imaging of hepatitis C virus to probe heterogeneous viral infection and responses to antiviral therapies. Virology 494:236-47
Luna, Joseph M; Scheel, Troels K H; Danino, Tal et al. (2015) Hepatitis C virus RNA functionally sequesters miR-122. Cell 160:1099-110
Swanson, Michael D; Boudreaux, Daniel M; Salmon, Loïc et al. (2015) Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity. Cell 163:746-58
Gres, Anna T; Kirby, Karen A; KewalRamani, Vineet N et al. (2015) STRUCTURAL VIROLOGY. X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability. Science 349:99-103
Tietjen, Ian; Ntie-Kang, Fidele; Mwimanzi, Philip et al. (2015) Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors. PLoS One 10:e0121099
Stoddard, Mark B; Li, Hui; Wang, Shuyi et al. (2015) Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. MBio 6:e02518
Kirby, Karen A; Ong, Yee Tsuey; Hachiya, Atsuko et al. (2015) Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247. FASEB J 29:70-80
Saeed, Mohsan; Andreo, Ursula; Chung, Hyo-Young et al. (2015) SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524:471-5

Showing the most recent 10 out of 31 publications